Qili Qiangxin as an Adjuvant Treatment with Inotrope for Advanced Heart Failure: Retrospective Analysis

Jinghai Hua, Ling Yu, Wenjun Xiong, Jianbing Zhu, Zhiming Gao, Yaofu Zheng, Dasong Yi, Xiaoping Peng and Zeqi Zheng

Background and Objective: Inotropic treatment is generally used for advanced chronic heart failure. However, a single administration of an inotropic agent is insufficient to produce long-lasting results. The objective of the study was to evaluate the clinical impact of adjuvant treatment of Qili Qiangxin capsules on inotropic agents on N-terminal pro-B-type natriuretic peptide (NTproBNP), hospitalization and quality of life of outpatients with advanced chronic heart failure. Materials and Methods: Patients who requiring the optimal medical management have received intermittent intravenous infusions of levosimendan plus oral Qili Qiangxin capsules (LN cohort, n = 67) or that of dobutamine plus oral Qili Qiangxin capsules (DB cohort, n = 62) or oral Qili Qiangxin capsules only (QQ cohort, n = 54). Results: At 12 weeks after intervention(s) (EL), NTproBNP was significantly decreased in patients of LN cohort than those of DB (p<0.0001, q = 6.555) and QQ (p<0.0001, q = 6.612) cohorts. Patients of LN cohorts had fewer all-cause hospitalization. At EL, only patients of the LN cohort had improved the Euro quality of life five-dimensional-five-level score (0.40±0.27 vs. 0.52±0.25, p = 0.019, q = 3.872) and the Kansas City Cardiomyopathy Questionnaire score (39.21±11.71 vs. 45.81±12.18, p = 0.004, q = 4.324) and had higher numbers of patients with normal the 6 min walking distance test value (3 vs. 15) as compared to before intervention(s). Conclusion: Qili Qiangxin capsules as an adjuvant treatment with intermittent intravenous infusions of levosimendan could be preferred for optimal medical management of advanced chronic heart failure patients to improve prognosis.

View Fulltext Back